Idiopathic Pulmonary Fibrosis Treatment Market To Reach $5.46 Billion By 2030

Idiopathic Pulmonary Fibrosis Treatment Market Growth & Trends

The global idiopathic pulmonary fibrosis treatment market size is expected to reach USD 5.46 billion by 2030, registering a CAGR of 6.8% from 2025 to 2030, according to a new report by Grand View Research, Inc. Increasing R&D initiatives undertaken by companies and surge in cigarette smoking population are anticipated to boost the growth.

Rise in the initiatives undertaken by manufacturers to develop products with novel mechanisms is anticipated to fuel the IPF treatment market growth. For instance, FibroGen, Inc., is currently developing a drug, pamrevlumab - a monoclonal antibody that targets the connective tissue growth factor. The phase III trials of pamrevlumab are expected to be initiated in the first half of 2019. The drug has received fast track designation from the Food and Drug Administration (FDA).

An aging population can be expected to have far-reaching social, economic, and political implications on nearly all the sectors including the healthcare sector. An associated consequence of an increase in the geriatric population will be an increase in the incidences of various medical conditions requiring long-term care. Moreover, the growing geriatric population base in countries with large untapped opportunities such as China and Japan is anticipated to drive the market growth during the forecast period.

The dramatic increase in cigarette smoking population is one of the major drivers likely to have a positive impact on market growth. According to the U.S. FDA and Centers for Disease Control and Prevention (CDC), in 2018, more than 3.6 million high and middle school students were existing e-cigarette users. The number increased by 1.5 million since the last year. The uptake in the use of e-cigarette is expected to lead to the incidence of IPF.

 Request a free sample copy or view report summary: Idiopathic Pulmonary Fibrosis Treatment Market Report

Idiopathic Pulmonary Fibrosis Treatment Market Report Highlights

• Pirfenidone dominated the market and accounted for a share of 43.0% in 2024.

• Orally administered medications led the market with a revenue share of 69.3% in 2024. Pirfenidone and nintedanib enhance patient compliance compared to injectable therapies.

• Hospital pharmacies held the largest revenue share 62.9% in 2024, as hospitals are equipped with advanced diagnostic tools for accurate IPF diagnosis and monitoring, facilitating timely treatment initiation.

• U.S. led in 2024 due to high market penetration and high awareness pertaining to IPF

Idiopathic Pulmonary Fibrosis Treatment Market Segmentation

Grand View Research has segmented the global idiopathic pulmonary fibrosis treatment market based on drug class, route of administration, distribution channel, region:

Idiopathic Pulmonary Fibrosis Treatment Drug Class Outlook (Revenue, USD Million, 2018 - 2030)

• Pirfenidone

• Nintedanib

• Interferon Gammato1b

• Others

Idiopathic Pulmonary Fibrosis Treatment Route Of Administration Outlook (Revenue, USD Million, 2018 - 2030)

• Oral

• Injectable

• Others

Idiopathic Pulmonary Fibrosis Treatment Distribution Channel Outlook (Revenue, USD Million, 2018 - 2030)

• Hospital Pharmacies

• Retail Pharmacies

• Others

Idiopathic Pulmonary Fibrosis Treatment Regional Outlook (Revenue, USD Million, 2018 - 2030)

• North America

  • U.S.

  • Canada

  • Mexico

• Europe

  • UK

  • Germany

  • France

  • Italy

  • Spain

  • Denmark

  • Sweden

  • Norway

• Asia Pacific

  • Japan

  • China

  • India

  • Australia

  • South Korea

  • Thailand

• Latin America

  • Brazil

  • Argentina

• Middle East & Africa

  • South Africa

  • Saudi Arabia

  • UAE

  • Kuwait

List Of Key Players Idiopathic Pulmonary Fibrosis Treatment Market

• F. Hoffmann-La Roche Ltd

• Boehringer Ingelheim International GmbH

• Bristol-Myers Squibb Company

• Medicinova, Inc

• Merck & Co., Inc.

• Galapagos NV

• Novartis AG

• Fibrogen, Inc.